Limited time75% off all plans
Get the app

Graft-versus-host disease

Graft-versus-host disease

Graft-versus-host disease

On this page

Pathophysiology - Donor's Deadly Attack

  • Mechanism: Immunocompetent donor T-cells from the graft recognize the recipient's tissues as foreign, as the host is too immunocompromised to reject the graft.
  • Key Players: Donor CD4+ and CD8+ T-cells react to the host's disparate Major Histocompatibility Complex (MHC) antigens.
  • Cascade: This triggers a massive inflammatory response, often called a "cytokine storm," leading to widespread tissue damage.

GVHD: Canonical and alternative mechanisms

Graft-versus-Leukemia (GVL) Effect: A beneficial "side effect" where donor T-cells also eliminate residual host cancer cells, particularly in hematopoietic stem cell transplants for leukemia.

  • Mnemonic (📌): Major targets are Skin, Liver, GI tract ("Some Lethal Grafts").

Clinical Presentation - Acute vs. Chronic Clash

FeatureAcute GVHDChronic GVHD
OnsetTypically < 100 days post-transplantTypically > 100 days post-transplant
MechanismDonor CD8+ T-cells attack host epithelial cellsDonor CD4+ T-cells & B-cells cause autoimmune, fibrotic process
SkinMaculopapular rash, erythema, bullae (may resemble SJS/TEN)Poikiloderma, scleroderma-like changes, lichen planus-like lesions
GI TractProfuse, watery/bloody diarrhea; nausea, vomiting; abdominal painEsophageal webs/strictures, malabsorption, weight loss
LiverJaundice, ↑ conjugated bilirubin & alkaline phosphataseCholestatic jaundice, potentially progressing to cirrhosis
Other-Sicca syndrome (dry eyes/mouth), bronchiolitis obliterans, myositis

⭐ Chronic GVHD is a major cause of late, non-relapse mortality following allogeneic transplant. It can arise de novo without any preceding acute GVHD.

Diagnosis & Prevention - Taming the Treachery

  • Diagnosis: Primarily clinical (maculopapular rash, diarrhea, ↑LFTs).
    • Biopsy is definitive: Shows lymphocytic infiltrate & apoptosis in skin, gut, or liver.
  • Prevention: The cornerstone of management.
    • HLA matching of donor and recipient is paramount.
    • Immunosuppressive prophylaxis is standard.
      • Calcineurin inhibitors (Cyclosporine, Tacrolimus)
      • Methotrexate

⭐ Biopsy of affected organs (skin, gut, liver) is the gold standard for diagnosis, revealing lymphocytic infiltration and apoptosis, which confirms the T-cell mediated assault.

High‑Yield Points - ⚡ Biggest Takeaways

  • In GVHD, transplanted donor T-cells attack recipient tissues, primarily after allogeneic bone marrow transplants.
  • Key targets are the skin (diffuse maculopapular rash), liver (jaundice, ↑ LFTs), and GI tract (profuse diarrhea).
  • The mechanism involves donor T-cells recognizing host MHC antigens as foreign.
  • Acute GVHD develops <100 days post-transplant; chronic GVHD develops >100 days.
  • Prophylaxis and treatment rely on immunosuppressive drugs like corticosteroids and cyclosporine.
  • A beneficial graft-versus-leukemia effect may also occur in cancer patients.

Continue reading on Oncourse

Sign up for free to access the full lesson, plus unlimited questions, flashcards, AI-powered notes, and more.

CONTINUE READING — FREE

or get the app

Rezzy — Oncourse's AI Study Mate

Have doubts about this lesson?

Ask Rezzy, your AI Study Mate, to explain anything you didn't understand

Enjoying this lesson?

Get full access to all lessons, practice questions, and more.

START FOR FREE